This study seems to me like comparing apples to oranges. I would think MORES should be more appropriately compared with OSTA (Osteoporosis Self-assessment Tool for Asians), which is also a questionaire based on purely clinical risk factors. Both OSTA and MORES identify patients who may be at higher risk for osteoporosis to get a BMD scan; whereas FRAX, which may take BMD into the computation, gives an estimate of the likelihood of a hip or spine fracture in the next 10 years, so as to inform advisability of starting treatment.
The value of MORES, apart from considering mainly male risk factors (COPD), lies in its 100% negative predictive value.
Prolia (Denosumab) trumps Aclasta (Zoledronic Acid) in bone mass density gain in postmenopausal women with Osteoporosis transiting from oral bisphosphonates.